Connect with us

Featured Stocks

Helix TCS Stock (OTCMKTS:HLIX): A Fundamentally Attractive Investment

Published

on

Helix TCS stock

Helix TCS Stock (OTCMKTS:HLIX) is turning out to be an interesting pick after a steep pullback in 2019. The stock appears to be trading at a big discount going by the solid fundamentals that support a bounce back from current lows. If you are looking for a company seeing plenty of opportunities on the horizon then Helix TCS stock fits the bill.

Helix TCS Stock Catalysts and Price Analysis

The company is currently ranked at number 32 on the Deloitte Technology 500 fastest growing companies. The impressive rating stems from the company reporting impressive financial results depicted by an 80% increase in revenue and a 39% increase in cash flow from operations.

Likewise, the company has moved to strengthen its prospects in the hemp business by launching the nation’s first hemp tracking system. Similarly, the company has inked a strategic partnership with Alt Thirty Six for the launch of digital payments targeting thousands of dispensaries across the U.S

Reports that Helix TCS BioTrack traceability stem processed over $11 million transactions in the first week of recreational sales attest to what could turn out to be a break out year for the company and its technology.

It thus does not come as a surprise that the company’s stock has started to pick up some steam after a roller coaster 2019. A 10% plus rally since the start of the year affirms renewed investor interest in response to the wave of positive developments in recent weeks.

After a recent spike higher, the stock faces immediate resistance at the $0.63 level as part of the bounce-back play. A rally followed by a close above the $0.63 level should open the door for the stock to make a run for the $0.77 mark, the next substantial resistance level.

The stock rising and finding support above the $0.77 mark should bring to an end the sell-off wave that had plunged the stock to all-time lows. Conversely, failure to take out the $0.63 level could leave the stock susceptible to further drops in continuation of the long-term bear trend.

About Helix TCS stock

Helix TCS casts itself as a leading provider of crucial infrastructure and technology that helps licensed cannabis businesses stay competitive in the multi-billion-dollar industry. The company boasts of an array of proprietary technology and security services used in enhancing supply management as well as asset protection. The company’s solutions are currently in use in over 2,000 customer locations in 38 states across the U.S and six countries.

BioTrack System Boost

Helix TCS sentiments and prospects have edged higher in the market on the confirmation that its proprietary BioTrack traceability system used in adult-use marijuana sales has processed over $11 million worth of sales.

On its first day of use in the state of Illinois, the system processed over $3.2 million in transactions with the numbers expected to continue increasing as the state continues to issue more licenses. The BioTrack system is designed to provide licensed cannabis operators a platform for managing business and maintaining compliance.

Digital Payment Opportunity

Likewise, Helix TCS has inked a partnership with Alt Thirty Six to enable digital payment payments in-store as well as online and on delivery services. The partnership will allow thousands of cannabis dispensaries across the U.S to accept digital payments consequently alleviate the risk of dealing with cash and credit cards.

“The primary mission of Helix Technologies is to be the leading provider of critical infrastructure services in the cannabis industry. By partnering with Alt Thirty-Six, we are able to provide our dispensary partners with yet another tool to help them run an efficient and compliant business,” said Moe Afaneh, COO at Helix BioTrack.

The unveiling of the BioTrack system in Illinois comes hot on the heels of the company launching an integrated hemp-tracking module in Delaware. The system allows operators to import hemp derivatives into medical cannabis products consequently ensuring patients get exactly what they asked for.

Bottom Line

The tide is slowly turning in favor of Helix TCS stock after coming under immense pressure in 2019. Improved operational efficiency with the launch of the BioTrack system is one of the key developments that continues to shape the company’s prospects.

Strategic acquisitions, as well as an increased focus on the customer and targeted internal improvements, should continue to drive growth and consequently shareholder value going forward. Improving fundamentals and positive developments provide clear evidence of positive trend materializing. In our view, Helix TCS stock looks set to continue bottoming out from current lows

We will be updating our subscribers as soon as we know more. For the latest updates on Helix TCS stock, sign up below!

Disclosure: We have no position in Helix TCS stock and have not been compensated for this article.

Featured Stocks

Decision Diagnostics Corp (OTCMKTS:DECN) Explodes On COVID-19 Test Kit Opportunity

Published

on

OTCMKTS:DECN

Decision Diagnostics Corp (OTCMKTS:DECN) is exploding higher after unveiling a new methodology for the screening of coronavirus. GenViroTM COVID-19 screening kit is the latest catalysts fuelling the stock’s price action activity in the market. Similarly, the stock has rallied by more than 300% as investors take note of the huge opportunity up for grabs as the coronavirus pandemic continues to cause havoc.

OTCMKTS:DECN Price Analysis

The ever-growing demand for coronavirus test kit presents a unique opportunity for the company to generate significant value. In return, investors have continued to push the stock higher even as the broader equity market continues to plunge into the bear territory.

OTCMKTS:DECN is currently trading in a steep uptrend after succumbing to bearish pressure in 2019. Given the strength of the upward momentum, the stock is closing in on its one-year highs as the break out shows no signs of slowing down. A rally followed by a close above the $0.08 mark should open the door for bulls to push the stock to two-year highs.

DECN Daily Chart

Similarly, the $0.05 mark is the immediate support level above which the stock remains a bull play. Conversely, a breach of the support level would leave Decision Diagnostics susceptible to further drops, probably back to the $0.03 level. However, given the developments on the global scene, the stock looks set to continue powering high on pullbacks.

About OTCMKTS:DECN

Decision Diagnostics bills itself…

Continue Reading

Featured Stocks

Is CytoDyn Inc. (OTCMKTS:CYDY) A Buy?

Published

on

CytoDyn

CytoDyn Inc (OTCMKTS:CYDY) has been making big moves lately, which have propelled the stock from December low of $0.270 to new highs. Notably, CytoDyn’s surge has come on significant volume as well, a clear sign of strong investor interest in the stock.

The excitement in CytoDyn stock that we are witnessing right now comes as the company has taken a leading role in the fight against the deadly Wuhan coronavirus. Moreover, investors have started pouring on CytoDyn stock as the company advances the development of its lead drug candidate as a treatment for about two dozen different cancer types.

Before we delve into the details, here is a brief profile of CytoDyn for those investors who may have just come across this company for the very first time.

About CytoDyn

CytoDyn operates in the healthcare sector as a biotechnology company. It is engaged in developing innovative treatments for a broad range of medical indications. Its lead product candidate is leronlimab (PRO 140). Clinical trials of leronlimab are ongoing for conditions such as HIV and multiple cancers with impressive results already attained. But CytoDyn is expanding its target conditions with leronlimab in the wake of the outbreak of the Wuhan coronavirus.

Here are some of the recent developments at CytoDyn that have excited renewed investor interest in its stock.

CytoDyn’s leronlimab under consideration as Wuhan potential coronavirus treatment

CytoDyn’s lead drug candidate leronlimab (PRO 140)…

Continue Reading

Featured Stocks

Rainmaker Worldwide Inc (OTCMKTS:RAKR) Looking For Bagholders

Published

on

Rainmaker Worldwide

On the OTC Markets, there are a lot of pump and dumps. Investors need to protect themselves from these types of scams and one, in particular, is Rainmaker Worldwide Inc (OTCMKTS:RAKR).

OTCMKTS:RAKR Price Action

While the price action recently has been positive, it’s just a matter of time before RAKR is trading in the double zeros again. It’s not a question of if it will happen, but when it will happen.

OTCMKTS:RAKR Daily Chart

About Rainmaker Worldwide

According to its profile, Rainmaker Worldwide Inc. is headquartered in Peterborough, Canada, with an innovation and manufacturing center in Rotterdam, Netherlands. Its patented water technology provides economical drinking water wherever it’s needed and at scale. Rainmaker builds two types of energy-efficient, fresh water-producing technologies to participate in this opportunity. 1. Air-to-Water, which harvests fresh water from humidity in the atmosphere. 2. Water-to-Water, which transforms seawater or polluted water into drinking water.

Lack of Fundamentals

The biggest concern facing investors is the lack of fundamentals. OTCMKTS:RAKR has a current market cap of $41 milli0n, but reported just $1000 in sales in the quarter ending September 30, 2019. Making matters worse is that Rainmaker burned through $524,000 in the quarter. Throughout its history, Rainmaker has lost $14.7 million.

EU Horizon 2020 Project and $2.5 million grant

Last September, Rainmaker touted the award of the European Union (EU) Horizon 2020 Project for Rainmaker’s Water to Water Product. According to the press…

Continue Reading

MJ Stocks